March 2026 in “Dermatology and Therapy” Distinct miRNA signatures could help diagnose and treat severe Alopecia Areata.
March 2026 in “Dermatology and Therapy” More severe alopecia areata can lower quality of life.
January 2026 in “Dermatology Practical & Conceptual” Nail changes are common in alopecia areata and can indicate its severity.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
January 2026 in “Clinical Cosmetic and Investigational Dermatology” Stressful life events may trigger alopecia areata.
December 2025 in “Cureus” Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.
November 2025 in “Frontiers in Medicine” The SAALIQ is a reliable tool for measuring the impact of alopecia areata on Spanish-speaking patients' quality of life.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
September 2025 in “Tạp chí Da liễu học Việt Nam” Combining oral methylprednisolone with microneedle radiofrequency improves hair growth in alopecia areata but may cause pain and side effects.
Dupilumab may cause hair loss, so patients should be monitored.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
July 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Microneedling can effectively promote hair regrowth in alopecia areata.
April 2025 in “PharmacoEconomics - Open” Patients with Alopecia Areata are willing to trade life duration for better quality of life.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
January 2025 in “International Journal of Dermatology Sciences” Nail changes in alopecia areata are common and may indicate severity and genetic risk.
October 2024 in “La Tunisie Médicale” Over half of alopecia areata patients in Tunisia experience depression, highlighting the need for psychological support.
September 2024 in “Turkish Journal of Dermatology” A lower second to fourth finger length ratio may predict male alopecia areata.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
March 2024 in “Clinical, cosmetic and investigational dermatology” Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.
November 2023 in “Pakistan Journal of Health Sciences” Clobetasol propionate 0.05% is more effective for hair re-growth in alopecia areata than tacrolimus 0.1%.
Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.
October 2023 in “Dermatologie pro praxi” Alopecia areata causes hair loss and has various treatment options, but responses differ.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
August 2023 in “Clinical and experimental dermatology and therapies” Dupilumab may help hair regrowth in some patients with severe atopic dermatitis, but results vary.
July 2023 in “Dermatology and therapy” People with alopecia areata may have a higher risk of blood clots.
July 2022 in “Al-Mağallaẗ al-ʻirāqiyyaẗ li-l-ṣaydalaẗ” Azelaic acid cream can effectively treat scalp hair loss.
January 2022 in “Al-Azhar Medical Journal” Higher antigliadin antibody levels are linked to alopecia areata severity.